Brief Summary

This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. HPV is known to cause a variety of cancers including cervical cancer. Even though there are ways to detect cervical cancer, many individuals are not diagnosed. Over half of all new cervical cancer cases are among those who have either never been screened or who are not screened enough. The low screening numbers show more testing needs to be done. Without appropriate screening and care, preventable precancer may turn into cancer. A new way to detect cervical cancer is to have individuals collect their own sample for HPV testing to know their risk for cervical cancer. This may give individuals more flexibility and comfort having the ability to collect samples themselves, compared to a doctor performing a speculum examination and collecting the samples in a clinic. Information gathered from this study compares clinical accuracy of HPV testing on self-collected vaginal samples versus cervical samples collected by clinician. The Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial is part of the National Cancer Institute (NCI)'s Cervical Cancer 'Last Mile' Initiative, a public private partnership that seeks to increase access to cervical cancer screening. The SHIP Trial focuses on developing clinical evidence to inform the US Food and Drug Administration (FDA)'s regulatory reviews of self-collection approaches as alternative sample collection approaches for cervical cancer screening. Several industry partner-specific self-collection device and assay combinations will be non-competitively and independently evaluated with a similar study design framework to inform pre-approval and/or post-approval regulatory requirements.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

500

participants targeted

Target at P75+ for not_applicable

Timeline

8mo left

Started Nov 2025

Geographic Reach

1 country

18 active sites

Status

recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

1.1 years study duration

Study Progress41%

Nov 2025Dec 2026

Study Start

First participant enrolled

November 24, 2025

Completed

18 days until next milestone

First Submitted

Initial submission to the registry

December 12, 2025

Completed

3 days until next milestone

First Posted

Study publicly available on registry

December 15, 2025

Completed

7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected

6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

February 17, 2026

Status Verified

December 1, 2025

Enrollment Period

7 months

First QC Date

December 12, 2025

Last Update Submit

February 13, 2026

Conditions

Cervical Carcinoma Human Papillomavirus Infection

Outcome Measures

Primary Outcomes (14)

Clinical sensitivity for self-collected (SC) samples
Will be defined as the probability of a positive SC sample given cervical intraepithelial neoplasia (CIN)2+. Will report point estimate and 95% confidence intervals (CIs).
One-time, up to 60 days
Clinical sensitivity for clinician-collected (CC) samples
Will be defined as the probability of a positive CC sample given CIN2+. Will report point estimate and 95% CIs.
One-time, up to 60 days
Clinical specificity for SC samples
Will be defined as the probability of a negative SC sample given \< CIN2. Will report point estimate and 95% CIs.
One-time, up to 60 days
Clinical specificity for CC samples
Will be defined as the probability of a negative CC sample given \< CIN2. Will report point estimate and 95% CIs.
One-time, up to 60 days
False positive rate (FPR) for SC samples
Will be defined as the probability of a positive SC sample given \< CIN2. Will report point estimate and 95% CIs.
One-time, up to 60 days
FPR for CC samples
Will be defined as the probability of a positive CC sample given \< CIN2. Will report point estimate and 95% CIs.
One-time, up to 60 days
False negative rate (FNR) for SC samples
Will be defined as the probability of a negative SC sample given CIN2+. Will report point estimate and 95% CIs.
One-time, up to 60 days
FNR for CC samples
Will be defined as the probability of a negative CC sample given CIN2+. Will report point estimate and 95% CIs.
One-time, up to 60 days
Sensitivity ratio for SC versus CC samples
Will be defined as the sensitivity of SC divided by the sensitivity of CC. Will report point estimate and 95% CIs.
One-time, up to 60 days
Specificity ratio for SC versus CC samples
Will be defined as the specificity of SC divided by the specificity of CC. Will report point estimate and 95% CIs.
One-time, up to 60 days
False positive (FP) ratio for SC versus CC samples
Will be defined as the FPR of SC divided by the FPR of CC. Will report point estimate and 95% CIs.
One-time, up to 60 days
False negative (FN) ratio for SC versus CC samples
Will be defined as the FNR of SC divided by the FBR of CC. Will report point estimate and 95% CIs.
One-time, up to 60 days
Positive percent agreement
Will be defined as the probability of positive on SC given positive on CC, expressed as a percent. Will report point estimate and 95% CIs.
One-time, up to 60 days
Negative percent agreement
Will be defined as the probability of negative on SC given negative on CC, expressed as a percent. Will report point estimate and 95% CIs.
One-time, up to 60 days

Other Outcomes (3)

Human factors affecting usability
One-time, up to 60 days
Human factors affecting acceptability
One-time, up to 60 days
Human factors affecting preferences for self-collection
One-time, up to 60 days

Study Arms (1)

Prevention (self-collected and clinician-collected samples)

EXPERIMENTAL

Patients undergo self-collection of a vaginal sample and then undergo clinician-collection of a cervical test sample. Patients then undergo SOC colposcopy with or without cervical biopsy/endocervical curettage and/or cervical excisional procedures as clinically indicated.

Procedure: Biospecimen CollectionProcedure: Cervical BiopsyProcedure: ColposcopyOther: Electronic Health Record ReviewProcedure: Endocervical CurettageProcedure: ExcisionProcedure: HPV Self-CollectionProcedure: Human Papillomavirus TestOther: Questionnaire Administration